Literature DB >> 15454649

Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis.

C P Hersh1, M Dahl, N P Ly, C S Berkey, B G Nordestgaard, E K Silverman.   

Abstract

BACKGROUND: Severe alpha(1)-antitrypsin deficiency, usually related to homozygosity for the protease inhibitor (PI) Z allele, is a proven genetic risk factor for chronic obstructive pulmonary disease (COPD). The risk of COPD in PI MZ heterozygous individuals is controversial.
METHODS: A search of MEDLINE from January 1966 to May 2003 identified studies that examined the risk of COPD in PI MZ individuals and studies that measured forced expiratory volume in 1 second (FEV(1)) in heterozygotes.
RESULTS: In 16 studies that reported COPD as a categorical outcome, the combined odds ratio (OR) for PI MZ versus PI MM (normal genotype) was 2.31 (95% CI 1.60 to 3.35). The summary OR was higher in case-control studies (OR 2.97; 95% CI 2.08 to 4.26) than in cross sectional studies (OR 1.50; 95% CI 0.97 to 2.31) and was attenuated in studies that adjusted for cigarette smoking (OR 1.61; 95% CI 0.92 to 2.81). In seven studies that reported FEV(1) as a continuous outcome there was no difference in mean FEV(1) between PI MM and PI MZ individuals.
CONCLUSIONS: Case-control studies showed increased odds of COPD in PI MZ individuals, but this finding was not confirmed in cross sectional studies. Variability in study design and quality limits the interpretation. These results are consistent with a small increase in risk of COPD in all PI MZ individuals or a larger risk in a subset. Future studies that adjust for smoking and include other COPD related phenotypes are required to conclusively determine the risk of COPD in PI MZ heterozygotes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15454649      PMCID: PMC1746834          DOI: 10.1136/thx.2004.022541

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  113 in total

1.  Convective gas mixing, airway dimensions and lung function parameters in patients homo- or heterozygote for hereditary alpha1-antitrypsin deficiency.

Authors:  R Siekmeier; C F Schiller-Scotland
Journal:  Toxicol Lett       Date:  1998-08       Impact factor: 4.372

2.  Bias in meta-analysis detected by a simple, graphical test.

Authors:  M Egger; G Davey Smith; M Schneider; C Minder
Journal:  BMJ       Date:  1997-09-13

3.  Alpha1-antitrypsin phenotypes and lung function in a moderately polluted northern Ontario community.

Authors:  D N Ostrow; J Manfreda; T Dorman; R M Cherniack
Journal:  Can Med Assoc J       Date:  1978-03-18       Impact factor: 8.262

4.  The PiMZ phenotype: is it a significant risk factor for the development of chronic obstructive lung disease?

Authors:  C Mittman
Journal:  Am Rev Respir Dis       Date:  1978-10

5.  Pi-Z phenotypes in a pulmonary clinic. Their prevalence and physiologic state.

Authors:  A A Gerblich; J Kleinerman; D J Rynbrandt; E H Chester; J Ihrig
Journal:  Am J Clin Pathol       Date:  1978-05       Impact factor: 2.493

6.  Intermediate alpha1-antitrypsin deficiency and chronic obstructive pulmonary disease in Yugoslavia.

Authors:  D Kozarevic; M Laban; M Budimir; N Vojvodic; A Roberts; T Gordon; D L McGee
Journal:  Am Rev Respir Dis       Date:  1978-06

7.  Assessment of alpha-1-antitrypsin deficiency heterozygosity as a risk factor in the etiology of emphysema. Physiological comparison of adult normal and heterozygous protease inhibitor phenotype subjects from a random population.

Authors:  D J McDonagh; S P Nathan; R J Knudson; M D Lebowitz
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

8.  Effect of environmental and clinical factors on lung function and respiratory symptoms in adolescents with alpha1-antitrypsin deficiency.

Authors:  E Piitulainen; T Sveger
Journal:  Acta Paediatr       Date:  1998-11       Impact factor: 2.299

9.  Intermediate alpha 1-antitrypsin deficiency PiSZ: a risk factor for pulmonary emphysema?

Authors:  N Seersholm; A Kok-Jensen
Journal:  Respir Med       Date:  1998-02       Impact factor: 3.415

10.  Z and S mutations of the alpha1-antitrypsin gene and the risk of chronic obstructive pulmonary disease.

Authors:  A J Sandford; T D Weir; J J Spinelli; P D Paré
Journal:  Am J Respir Cell Mol Biol       Date:  1999-02       Impact factor: 6.914

View more
  51 in total

1.  Clan genomics and the complex architecture of human disease.

Authors:  James R Lupski; John W Belmont; Eric Boerwinkle; Richard A Gibbs
Journal:  Cell       Date:  2011-09-30       Impact factor: 41.582

Review 2.  Progress in chronic obstructive pulmonary disease genetics.

Authors:  Edwin K Silverman
Journal:  Proc Am Thorac Soc       Date:  2006-07

3.  Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline.

Authors:  Darcy D Marciniuk; P Hernandez; M Balter; J Bourbeau; K R Chapman; G T Ford; J L Lauzon; F Maltais; D E O'Donnell; D Goodridge; C Strange; A J Cave; K Curren; S Muthuri
Journal:  Can Respir J       Date:  2012 Mar-Apr       Impact factor: 2.409

Review 4.  Association between polymorphism of tumour necrosis factor alpha-308 gene promoter and asthma: a meta-analysis.

Authors:  J Gao; G Shan; B Sun; P J Thompson; X Gao
Journal:  Thorax       Date:  2006-03-03       Impact factor: 9.139

5.  Rationale and Design of the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis Study. Alpha-1 Protocol.

Authors:  Charlie Strange; Robert M Senior; Frank Sciurba; Scott O'Neal; Alison Morris; Stephen R Wisniewski; Russell Bowler; Harry S Hochheiser; Michael J Becich; Yingze Zhang; Joseph K Leader; Barbara A Methé; Naftali Kaminski; Robert A Sandhaus
Journal:  Ann Am Thorac Soc       Date:  2015-10

Review 6.  National Emphysema Treatment Trial state of the art: genetics of emphysema.

Authors:  Craig P Hersh; Dawn L DeMeo; Edwin K Silverman
Journal:  Proc Am Thorac Soc       Date:  2008-05-01

Review 7.  Risk of Lung Disease in PI MZ Heterozygotes. Current Status and Future Research Directions.

Authors:  Edwin K Silverman
Journal:  Ann Am Thorac Soc       Date:  2016-08

Review 8.  Markers of early disease and prognosis in COPD.

Authors:  Morten Dahl; Børge G Nordestgaard
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-04-15

Review 9.  Genetics of chronic obstructive pulmonary disease.

Authors:  Carola Seifart; Alexandra Plagens
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

10.  Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency.

Authors:  Irina Petrache; Joud Hajjar; Michael Campos
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.